Lv1
80 积分 2025-11-11 加入
New and recurrent atrial fibrillation in obstructive hypertrophic cardiomyopathy patients receiving mavacamten
9天前
已完结
Atrial fibrillation in hypertrophic cardiomyopathy: A unique clinical entity requiring dedicated study
11天前
已关闭
Atrial fibrillation in hypertrophic cardiomyopathy: A unique clinical entity requiring dedicated study
11天前
已关闭
Aficamten: First Approval
11天前
已完结
IMPORTANCE OF THE SURGICAL MYECTOMY OPTION IN THE CHANGING LANDSCAPE OF MANAGEMENT FOR SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
11天前
已完结
The Physiology of Flow Cessation: A Call for Inclusion of Continuous-Wave Doppler Interrogation of the Mid-apical Left Ventricle in the Standard Hypertrophic Cardiomyopathy Protocol
11天前
已关闭
Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study
1个月前
已完结
Transcatheter Edge‐to‐Edge Repair for Hypertrophic Cardiomyopathy
1个月前
已完结
Long-term safety and efficacy of aficamten in the evolving era of myosin inhibition for obstructive hypertrophic cardiomyopathy
1个月前
已完结
皖公网安备34019202002308
